Business Casual: NFL and EA Extend Madden Video Game Contract Through 2026

 

Selling more than 130 million copies since it started in 1989, thus, making it one of two video sports games ever to sell more than 100 million copies, the Madden franchise will continue to be a part of the gaming world for at least the next six years. Recently approving an extension of their contract that was set to expire after the 2021 season, the NFL and Electronic Arts (EA) are continuing a relationship that has existed for 30 years, making EA Sports the league’s exclusive publisher of football simulation games through 2026. Worth $1 billion to the NFL and $500 million to the players, as well as $500 million in marketing commitments, this deal tightens the ‘Madden’ grip on the video game market.

NFL VP-Head of Gaming and eSports Rachel Hoagland believes that keeping the Madden franchise at the core of the league’s video gaming strategy is vital, commenting, “EA has done a nice job of ensuring the game matches the experience during a game week. The new technology will allow richer content and add more realism.”

Daniel Litwin, Taylor Bagley, and Tyler Kern take on all things pigskin on this Business Casual snippet. First, the hosts break down the various parts of the new contract, EA’s exclusive rights to NFL simulation games that have existed since 2005 versus the NFL’s recent deal with 2K to debut a non-simulation (arcade-style) NFL game, and the loosening of NCAA football videogame licensing restrictions that will now allow college players to profit off their likenesses. But the Business Casual tag-team also discuss how optimistic conversations centered around the NHL, NBA and MLB reopening their seasons soon will impact the NFL’s decision to retake the field, as well as the NFL Players Association’s stance on player safety.

Coming to you each Wednesday and Friday, MarketScale’s Business Casual brings thought leadership to your day, keeping you current with the hottest topics and newest trends shaping business, culture and sports. And for the latest thought leadership, news and event coverage across B2B, be sure to check out our industry pages.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More